<DOC>
	<DOCNO>NCT00076037</DOCNO>
	<brief_summary>The effectiveness vaccine improve use `` prime boost strategy '' use adjuvant . A prime boost strategy administration one type vaccine ( primer ) follow administration another type vaccine ( booster ) . An adjuvant substance enhance immune response give time vaccine . This study evaluate safety immune response vaccine design used part prime boost strategy . The study also evaluate vaccine give adjuvant . The vaccine study produce live HIV infect cell . It contain HIV , cause HIV infection .</brief_summary>
	<brief_title>Safety Immune Response New HIV Vaccine : HIV CTL MEP</brief_title>
	<detailed_description>Prime-boost vaccine strategy aim induce different type immune response enhance overall immune response , result may occur single type vaccine . This trial evaluate safety immunogenicity HIV multi-epitope peptide cytotoxic T lymphocyte ( HIV CTL MEP ) vaccine develop part prime-boost strategy design administer combination HIV DNA vaccine . The HIV CTL MEP vaccine mixture four synthetic peptide , contain one three different HIV CTL epitopes derive env gag . The use multiple conserve CTL epitope address extraordinary diversity find among HIV strain . The vaccine administer RC529-SE , analogue monophosphoryl lipid A . The vaccine/adjuvant combination evaluate without coadministration granulocyte-macrophage colony-stimulating factor ( GM-CSF ) . Participants randomly assign receive either vaccine RC529-SE adjuvant , vaccine adjuvant ( RC529-SE GM-CSF ) , placebo . The vaccine , adjuvant , placebo give injection upper arm . Participants 11 study visit . Study visit include physical exam , medical interview , blood urine test . Participants receive injection three visit : study entry Months 1 3 . Participants follow 1 year last injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HIV uninfected Willing receive HIV test result Good general health One follow major histocompatibility ( MHC ) alleles : HLA A3 , B7 , B8 Acceptable method contraception female reproductive potential Hepatitis B surface antigen negative Antihepatitis C virus antibody ( antiHCV ) negative negative HCV PCR antiHCV positive Access participate site available followup 15 month study HIV vaccine placebos prior HIV vaccine trial Immunosuppressive medication within 168 day prior first study vaccine administration Blood product within 120 day prior first study vaccine administration Immunoglobulin within 60 day prior first study vaccine administration Live attenuate vaccine within 30 day prior first study vaccine administration Investigational research agent within 30 day prior first study vaccine administration Subunit kill vaccine within 14 day prior first study vaccine administration Current tuberculosis prophylaxis therapy Serious adverse reaction vaccine . A person adverse reaction pertussis vaccine child exclude . Hypersensitivity egg product yeastderived product Autoimmune disease immunodeficiency Active syphilis Unstable asthma Type 1 Type 2 diabetes mellitus Thyroid disease require treatment past 12 month Serious angioedema within past 3 year Uncontrolled hypertension Bleeding disorder Malignancy unless surgically remove , opinion investigator , likely recur study period Seizure disorder require medication within past 3 year Asplenia Mental illness would interfere compliance protocol Other condition , judgment investigator , would interfere study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Injections , Intramuscular</keyword>
	<keyword>RC529</keyword>
	<keyword>Epitopes</keyword>
	<keyword>T-Lymphocytes , Cytotoxic</keyword>
</DOC>